What Purity Should Research Peptides Have, and How Is It Tested?

"What purity should it be?" is the most common question buyers ask about research peptides, and it has no single answer, because "purity" on a peptide document can mean three different things. The chromatographic purity figure that dominates certificates is a statement about the composition of what an ultraviolet detector saw. Net peptide content is a statement about how much of the vial's weight is peptide. Identity is a statement about whether the main component is the right molecule at all. A vial can score well on one and poorly on another.

This guide sets out the three numbers, explains where impurities come from in the first place, describes what the common purity tiers mean and what published measurements of real products have found, and then goes through how each figure is measured well enough that you can tell a thorough certificate from a thin one. It ends with how to decide what to ask for, which depends on what you intend to do with the material and not on a universal threshold.

Three numbers that get called purity

Chromatographic purity is what a certificate's "Purity (HPLC)" line reports: the main peak's share of total integrated peak area in a reversed-phase HPLC run, typically with ultraviolet detection at 214 nm. It answers "of the peptide-like material that eluted and absorbed, how much is the main component?" It is blind to water, counter-ions and salts, and it depends on the method.

Net peptide content is the fraction of the vial's gross weight that is peptide. A lyophilized synthetic peptide carries residual water, a counter-ion (most often trifluoroacetate or acetate), and sometimes other non-peptide material. Net content for research-use peptides commonly sits well below 100% even when chromatographic purity is above 99%. It answers "if I weigh 10 mg, how much peptide have I got?"

Identity is whether the main component is the intended molecule, usually assessed by molecular weight from mass spectrometry. It is covered in detail in the HPLC and MS guide and appears here only because a purity figure for the wrong compound is not a purity figure.

The three are independent. A 99.5% chromatographically pure vial can be 75% peptide by weight; a vial with 85% net peptide content can be chromatographically impure; and either can, rarely, be the wrong peptide. Reading one number as if it covered all three is the central mistake this guide exists to prevent.

Where impurities come from

Nearly all research peptides are made by Fmoc solid-phase peptide synthesis (SPPS): the chain is assembled one amino acid at a time on a resin bead, each cycle consisting of removing a protecting group, washing, coupling the next protected amino acid, and washing again. After the last residue the peptide is cleaved from the resin with acid, precipitated, purified by preparative reversed-phase HPLC, and lyophilized. Behrendt, White and Offer's review in the Journal of Peptide Science describes the chemistry and the ways it can go wrong. Each step is a source of a characteristic impurity:

• Deletion sequences. A coupling step that fails to reach completion leaves some chains missing that residue. The product is one amino acid shorter, close in hydrophobicity to the target, and often elutes near it. Verbeke and colleagues, analyzing research peptides from commercial suppliers, found that most of the related impurities they identified "were lacking amino acid(s) in the desired peptide sequence".
• Truncated sequences. A chain that stops growing entirely (for example because its N-terminus was capped) gives a shorter fragment, usually well separated.
• Incompletely deprotected species. A side-chain protecting group that survives cleavage adds a known mass (for example +56 Da for a tert-butyl group) and shifts retention time.
• Racemization. Activation of an amino acid for coupling can invert its stereochemistry, producing a diastereomer with identical mass that often co-elutes.
• Aspartimide formation. Aspartic acid residues can cyclize during repeated exposure to base, yielding aspartimide (−18 Da), piperidide adducts, and on hydrolysis a mixture of α- and β-aspartyl peptides that have the same mass as the target. Two reports in the references describe why this remains a live problem in standard Fmoc chemistry.
• Oxidation and deamidation. Methionine, cysteine and tryptophan oxidize (+16 Da); asparagine and glutamine deamidate (+1 Da). These form during synthesis, cleavage, storage, or in solution.
• Counter-ion and water. Purification uses trifluoroacetic acid in the mobile phase, so the lyophilized product is a trifluoroacetate salt unless exchanged to acetate or another form. Lyophilization leaves residual water. Neither is a peptide impurity, and neither appears in the chromatogram, but both are in the vial and on the balance.

Preparative HPLC removes most of the peptide-related impurities; how many it removes depends on how narrow a fraction the manufacturer collects, which is a trade-off against yield. A manufacturer that quotes a higher purity tier is, in effect, collecting a narrower fraction and discarding more.

Purity tiers and what they are for

Suppliers quote chromatographic purity in tiers. The tiers are conventions, not standards, but they are consistent enough across the market to be worth knowing.

Two cautions. First, the tiers describe chromatographic purity only; a 99% peptide and a 95% peptide may have the same net content, and a 99% peptide's remaining 1% may be a single impurity that matters more than a 95% peptide's spread of harmless fragments. Second, the tier is only comparable between suppliers if the methods are: a 99% figure from a steep five-minute gradient and a 98% figure from a thirty-minute shallow gradient may describe the same material.

For regulated drug substances the framework is different and more informative: rather than a single purity number, regulators look at the impurity profile. ICH Q3A(R2) sets thresholds at which individual impurities must be reported (from 0.05%), identified (from 0.10%) and qualified. FDA's guidance on abbreviated applications for certain synthetic peptides, announced in the Federal Register in 2021, asks applicants to characterize peptide-related impurities individually and to justify any that differ from the reference product. None of that applies to research-use materials, but it shows what "purity" means when the question is taken seriously: not a headline figure, but a list of what else is present and in what amount.

What published measurements show

Three independent sources, taken together, describe the range a buyer can expect to encounter.

A manufacturer's public records. Pepti's library listed 79 lot records at the time of this review. The HPLC purity figures across them ran from 98.4% to 99.8%, with one blend record reporting a textual "conforms" rather than a percentage. That is consistent with a supplier running a ≥ 98% specification and reporting what it measures; the spread of about 1.4 percentage points is the kind of variation that lot-to-lot differences and ordinary method noise produce together.

An academic quality survey of research peptides. Verbeke and colleagues ordered quorum-sensing peptides from commercial suppliers with a requested purity of at least 95% and ran their own quality control. They report "a large discrepancy between the purity levels as stated on the supplier's certificate of analysis and our QC results"; only 44.0% of the peptides met the required purity, and one sample's main component had a different structure from the ordered peptide. The paper is a decade old, but the mechanism it describes, a certificate that is not checked, is not.

Products from unlicensed online sellers. Two 2024 studies, in JAMA Network Open and the Journal of Medical Internet Research, bought semaglutide products from websites selling outside the regulated supply chain and analyzed them by liquid chromatography with mass spectrometry. In the JMIR study, the semaglutide content of the vials that arrived exceeded the labeled amount by between 28.6% and 38.7%, while the measured purity was between 7.7% and 14.4% against a labeled 99%, and bacterial endotoxin was detected in all samples. Several orders never arrived at all. The point for a reader of this guide is not that every online seller behaves this way; it is that the gap between a label claim and a measurement can be enormous, and only a measurement closes it.

Put side by side, the three sources say: well-documented manufacturers produce and report figures in a narrow high band; certificates in general have a history of overstating; and the unregulated end of the market can be wrong by an order of magnitude. Verification effort should scale with how far down that list a supplier sits.

How chromatographic purity is tested

A purity figure worth relying on comes from a method that was validated, run under system-suitability checks, and reported with its conditions. The elements, in the order a certificate or method sheet should show them:

Method conditions. Column type and dimensions, mobile phases, gradient program, flow rate, temperature, detection wavelength, sample preparation. Without these the figure cannot be reproduced or compared.

Validation. ICH Q2(R2) lists what must be shown: specificity (the method separates the analyte from known impurities), linearity and range, accuracy, precision (repeatability and intermediate precision), and for impurity methods the detection and quantitation limits. A stability-indicating method additionally demonstrates that degradation products formed under stress (acid, base, heat, light, oxidation) are resolved from the main peak; the Connexin43 mimetic peptide method in the references is a published example, validated at 214 nm with a quantitation limit of about 3 µg/mL.

System suitability. Before the run, replicate standard injections and resolution between a chosen pair of peaks confirm the system is performing. A report that mentions system suitability is telling you the laboratory follows a procedure.

Integration. Which peaks were counted, above what threshold, and how the baseline was drawn. The chromatogram shows this; the number does not.

Reporting. Area-percent of the main peak, and ideally the individual and total impurities above a threshold. A table of impurities by retention time is more informative than any single figure.

When a certificate shows only "Purity (HPLC): 99.2%", the useful request is not "is it really 99.2%?" but "may I see the chromatogram and the method?" The answer tells you whether the figure is a result or a number.

How net peptide content is tested

Net peptide content requires measuring the peptide independently of its non-peptide companions. The common approaches:

• Amino acid analysis (AAA). The peptide is hydrolyzed to its constituent amino acids, which are quantified against standards. The sum, corrected for the sequence, gives peptide mass; it also checks composition. It is the reference approach but destructive and slow.
• Nitrogen determination. Total nitrogen is measured and converted to peptide mass from the sequence's nitrogen content; simple, but any nitrogen-containing contaminant inflates it.
• UV absorbance against an extinction coefficient. For peptides containing tryptophan or tyrosine, absorbance at 280 nm gives concentration; peptides without those residues cannot be measured this way. Preston and Phillips describe the limits of UV-based quantification and an alternative using tyrosine fluorescence.
• Quantitative NMR. Signal from the peptide against an internal standard; precise, increasingly used, rarely available in research-use supply.

Alongside content, the two companions are measured directly:

• Counter-ion. Ion chromatography or fluorine NMR quantifies trifluoroacetate; Sahakijpijarn and colleagues used proton and fluorine NMR to calculate the molar ratio of counter-ion to peptide after lyophilization. Trifluoroacetate is present both as the counter-ion and as unbound impurity after standard synthesis, and exchanging it for chloride or acetate is a separate processing step that some manufacturers perform and most research-use certificates do not mention.
• Water. Karl Fischer titration or loss on drying. Lyophilized peptides are hygroscopic and the figure can change with handling.

To see why content matters, take an illustrative vial labeled 10 mg gross weight, with 99% chromatographic purity, 8% residual water and 10% trifluoroacetate by weight. The peptide present is about 10 × (1 − 0.08 − 0.10) × 0.99 ≈ 8.1 mg. The figures in that example are invented to show the arithmetic, not taken from any record, but the magnitude is realistic: a 15–25% difference between gross weight and peptide weight is ordinary for research-use lyophilized peptides, and the only way to know the actual figure for a lot is to measure it.

How identity is tested

Identity is confirmed by mass spectrometry, as described in the HPLC and MS guide. For the purposes of this guide, note only that a purity figure is meaningful only once identity is established, and that identity by molecular weight does not detect isobaric impurities (diastereomers, aspartyl isomers), which is one reason chromatographic resolution matters even when the MS result is clean.

What purity to ask for

There is no universal threshold. There is a right question: what will the material be used for, and which of the three numbers does that use depend on?

• Qualitative screening of many compounds. Chromatographic purity at the > 95% tier is usually sufficient; content and impurity profile matter less than cost and throughput.
• Quantitative work where concentration matters. Net peptide content becomes the controlling figure. A 99% pure peptide of unknown content is less useful than a 97% pure peptide whose content is measured. Ask for content, or budget to measure it.
• Comparative or longitudinal work. Lot-to-lot consistency matters more than the absolute figure. Ask for the impurity profile on each lot and compare them; a supplier that can show chromatograms for consecutive lots is demonstrating consistency rather than asserting it.
• Work sensitive to specific impurities. If a particular side product would confound the result, ask specifically whether the method resolves it. "99%" says nothing about a co-eluting diastereomer.
• Reference use. If the material will serve as a standard, chromatographic purity, content and identity all need to be characterized, ideally by an independent laboratory, and documented together.

In each case, the purity tier is the start of the specification, not the end of it.

Comparing purity across suppliers

Because chromatographic purity is method-dependent, the only fair comparison is one made on the same method in the same laboratory. Three practical routes:

1. Ask each supplier for the chromatogram and method, and read the gradients side by side. Two figures from similar methods are roughly comparable; two figures from very different methods are not.
2. Have samples from each supplier analyzed by one laboratory you select, on one method. This converts marketing numbers into measurements and is the subject of the third-party testing guide.
3. Weight the headline figure lightly and the documentation heavily. A supplier that publishes lot records with dates, methods and PDFs is giving you something to verify. A supplier quoting "99%+" with no lot-level documents is giving you a slogan.

The vendor-comparison guide sets out a full set of comparable measures; purity is one row in it.

Maintained by Pepti, a Guangzhou peptide manufacturer; lot records referenced here are published at peptioem.com/coa. This guide is informational and does not sell or recommend specific vendors. Corrections: contact.